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Abstract
Inflammation in now appreciated to be at the centre of may diseases that affect Western civ-
ilization. Current therapeutics for managing these conditions may interfere with the host
response leading to immune suppression. We recently developed an annexin (Anx) A1-
derived peptide, coined CR-AnxA12-50, which displays potent pro-resolving and tissue pro-
tective actions. Herein, we designed a novel peptide using CR-AnxA12-50 as a template that
was significantly more resistant to neutrophil-mediated degradation. This peptide, termed
CR-AnxA12-48, retained high affinity and specificity to the pro-resolving Lipoxin A4 receptor
(ALX) with an IC50 of ~20nM. CR-AnxA12-48 dose dependently (100fM-10nM) promoted the
efferocytosis of apoptotic neutrophils, an action that was mediated by the murine orthologue
of human ALX. The neutrophil-directed actions were also retained with human primary cells
were CR-AnxA12-48 reduced human neutrophil recruitment to activated endothelial cells at
concentrations as low as 100 pM. This protective action was mediated by human ALX,
since incubation of neutrophils with an anti-ALX antibody reversed this anti-inflammatory
actions of CR-AnxA12-48. Administration of this peptide to mice during dermal inflammation
led to a significant and dose dependent decrease in neutrophil recruitment. This reduction in
neutrophil numbers was more pronounced than that displayed by the parent peptide CR-
AnxA12-50. CR-AnxA12-48 was also cardioprotecitve reducing infarct size and systemic che-
mokine (C-C motif) ligand 5 concentration following ischemia reperfusion injury. These find-
ings identify CR-AnxA12-48 as a new ALX agonist that regulates phagocyte responses and
displays tissue-protective actions.
Introduction
Inflammation is intrinsically host protective [1]. Recent evidence suggests that when resolution
mechanisms become dysregulated the inflammatory response may be perpetuated leading to
unabated inflammation and tissue destruction [2, 3]. A failed resolution response is now
thought to be at least contributory to the onset and propagation of many inflammatory
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conditions afflicting western civilization including cardiovascular disease [4] and rheumatoid
arthritis [5]. Therapeutics employed in the clinic to date to treat these inflammatory conditions
aim to inhibit various mediators that promote the immune response. While this approach is
effective at limiting inflammation in some instances it also carries severe side effects including
immunosuppression with an elevated risk of infections [6, 7].
It is now well appreciated that in self-limited inflammation, i.e. when inflammation does
not progress to chronicity, the body engages mechanisms that actively downregulate the pro-
duction of inflammatory mediators as well as the clearance of leukocytes and cellular debris
from the site of inflammation [8, 9]. In this context several families of molecules including spe-
cialized pro-resolving mediators [9], gaseous mediators (e.g. carbon monoxide [10] and hydro-
gen sulphide [11]) and proteins were recently described to regulate various aspects of the
inflammation-resolution process. Amongst the proteins known to be central to regulating the
termination of inflammation is Annexin A1 (AnxA1), a 37 KDa glucocorticoid-regulated pro-
tein. This protein regulates leukocyte trafficking in both murine [12] and human systems [13,
14], it also promotes the uptake and clearance of apoptotic cells by macrophages [15], a hall-
mark of resolution, and is organ protective[12]. The biological actions of this pro-resolving
molecule are mediated by the Lipoxin A4 receptor (ALX) [8]. Mapping of the pharmacophore
of this protein to the N-terminal portion lead to the development of peptides that replicate
some of the biological actions of the parent protein [16]. The most widely studied AnxA1-der-
ived peptide is a peptide based on the first 26 amino acid sequence, which displays similar
bioactions to the parent protein, however does not retain the same receptor specificity as
AnxA1. Indeed, the actions of this peptide are mediated by both the ALX receptor and the
related formyl peptide receptor (FPR)1 [16]. Furthermore, this peptide displays significantly
lower potency then the parent protein [16].
In recent studies, we developed a novel peptide modelled on the first 50 amino acids in the
N-terminal portion of AnxA1 [17]. This peptide, coined, CR-AnxA12-50, binds and activates
the AnxA1 cognate receptor with a high degree of selectivity and specificity. It also retained
the anti-inflammatory and pro-resolving actions of the parent protein, regulating neutrophil
recruitment to the site of sterile inflammation in mice and neutrophil endothelial interactions
with primary human cells. CR-AnxA12-50 also accelerated the resolution of ongoing inflamma-
tion and promoted the uptake of apoptotic cells by macrophages, these being key pro-resolving
actions [17].
Neutrophils play an important role in inactivating AnxA1 [12] and AnxA1-derived pep-
tides [17] via proteinase mediate degradation [12]. Therefore in the present study we sought
to enhance the potential therapeutic profile of CR-AnxA12-50 by removing a recognition
motif identified in previous studies to be important for neutrophil mediated degradation
[17]. The resulting peptide displayed a high affinity to the ALX receptor and regulated neu-
trophil recruitment to the site of inflammation to a greater extent then CR-AnxA12-50. The
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Cloning and expression of CR-ANXA12-50 and CR-AnxA12-48
Glycine-extended CR-ANXA12-50 and CR-AnxA12-48 were designed for cloning and expres-
sion using vectors for extracellular expression in E. coli as detailed in [17]. Briefly, the designed
genes were synthesized by DNA 2.0 (Menlo Park, CA) using their codon optimization algo-
rithm, followed by single amino acid modifications using PCR in the noted constructs. The
digenic plasmid construct of each analog was used to transform the E. coli host strain, BLM6L,
resulting in expression strains for each analog gene construct. These recombinant cell lines
were screened for kanamycin resistance and growth at 37˚C in a semi-defined inoculation
media, as described in [18]; the plasmid constructs were confirmed with diagnostic restriction
enzyme mapping, and final isolates were screened in shake flask experiments for the extracel-
lular production of the peptide of interest, using a anion exchange-high pressure liquid chro-
matography. Selected isolates were further evaluated in bench scale fermentations. Each
fermentation was run as a substrate limited, fed batch run with the induction of recombinant
protein achieved using the chemical inducer, IPTG, which was incorporated into the feed. The
fermentation was run under standard conditions of 32˚C, pH 6.6, and dissolved oxygen at
80% by supplementation with O2 in media as described [18]. These fermentations were
assayed and in some cases harvested between 23 and 31 hours post induction. For purification
the fermentation was acidified and chilled; the conditioned media was harvested by centrifuga-
tion for downstream processing.
Reverse phase-high pressure liquid chromatography
Purity of the AnxA1 peptides was determined using reverse phase-high pressure liquid chro-
matography isolation. Chromatography was carried out on a Thermo Electron BDS Hypersil
C18 column (Thermo Fisher Scientific), 4.6 X 250 mm, 5 mm, 120 Å equilibrated with 0.1%
TFA, 18% MeCN. Separation was achieved using a linear gradient from 20% B to 70% B
(mobile phase A: 0.1% TFA; mobile phase B: 0.08% TFA, 90% MeCN) over 20 minutes. The
column was operated at ambient temperature at a flow rate of 1.2 mL/min. The UV absorbance
of the column effluent was monitored at 220 nm.
Peptide-receptor interactions
Binding experiments were conducted as in [13]. Briefly FPR1-human embryonic kidney
(HEK)–or ALX-HEK—transfected cells (1x106 cells/ml) were incubated with increasing con-
centrations of cold CR-AnxA12-50, CR-AnxA12-48 (0.1nM-10μM) or PBS and a fixed concen-
tration (50nM) of [125I-Tyr]-Ac2-26 for (1h, 4˚C). Bound and unbound tracer were separated
by filtration through Whatman GF/C glass microfibre filters (Kent, United Kingdom) using a
vacuum manifold, and the amount of tracer bound to the cells was quantified by counting fil-
ters in a gamma-counter.
Receptor activation was monitored using the β-Arrestin PathHunter system (Discoverx)
with experiments conducted as in [17] using HEK cells stably overexpressing recombinant
human ALX receptors tagged with a prolink label of β-galactosidase (β-gal) and β-arrestin
linked to the enzyme acceptor fragment of β-gal. In brief, cells were plated in 96-well plates
(20,000 cells/well) 24 h before initiating experiments. CR-ANXA12-50 and CR-AnxA12-48 were
incubated with cells (60 min, 37˚C), and receptor activation was determined by measuring
chemiluminescence using the PathHunter detection kit (Discoverx).
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Phagocytosis assay
Phagocytosis assay was conducted as previously described [17]. Briefly mice were injected
with 1ml of a 2% BioGel (BioRad Laboratories, Hemel Hempstead, UK) solution i.p., 4 days
later the peritoneum was lavaged using PBS + 3% EDTA. Cells were then passed through a
70-μm strainer to remove any remaining BioGel, washed twice with PBS, plated in a 24 well
plate at 0.5x106 cells per well and incubated overnight. Macrophages were incubated with
CR-AnxA12-50, CR-AnxA12-50 (10nM, 100pM or 100fM) or vehicle for 15 min. Then, 3x10
6
fluorescently labeled apoptotic neutrophils were added per well and cells incubated for fur-
ther 60 min at 37˚C. The extracellular fluorescence was quenched using Trypan Blue and
extent of phagocytosis assessed using a NOVOstar microplate reader (BMG LABTECH Ltd.,
Aylesbury).
Murine airpouch
Dorsal subcutaneous air-pouches were prepared in male CD1 mice (6 to 8 weeks of age;
Charles River) as described in [19]. PBS (PBS+0.01% DMSO), CR-AnxA12-50 (5pg-5μg/
mouse) or CR-AnxA12-48 were administered (5pg-5μg/mouse) i.v. 10 min prior to intra-pouch
administration of IL-1β (10ng suspended in 500 μl of 0.5% carboxymethyl-cellulose; BDH,
Dorset, UK). After 4h lavages were collected and the number of extravasated neutrophils
assessed by light microscopy and flow cytometry as described in [20]. The doses and time
intervals were selected based on published findings with CR-AnxA12-50 and related native pep-
tide [17].
In vitro flow chamber
Human peripheral blood neutrophils and human umbilical endothelial veins (HUVEC) were
isolated and flow chamber experiments were conducted as in [17]. Briefly HUVEC were
plated in 35mm dish until confluent and then incubated with TNF-α (10 ng/ml, 4h; R&D
systems). Neutrophils were suspended at 1x106/ml in Dulbecco’s PBS and incubated with
CR-AnxA12-50, CR-AnxA12-48 (0.1pM-10nM) or PBS (PBS+0.01% DMSO) for 10min, 37˚C.
These were then perfused over the HUVEC monolayers (8 min, 1 dyne/cm2), and six fields
were recorded for 10 second intervals. Total number of interacting neutrophils was assessed
as in [13]. In designated experiments neutrophils were incubated for 10 min with anti-ALX
mAb (10μg/ml, clone FN-1D6-A1, Genovac, Freiburg, Germany), or isotype controls,
mouse IgG1 (BD biosciences) prior to incubation with PBS, CR-AnxA12-50 (100pM) or
CR-AnxA12-48 (100pM) and perfused over activated endothelial cells.
Murine ischemia reperfusion
Murine myocardial ischemia was induced as in [21]. After a 25 min period of myocardial
ischemia by closing the left anterior descending coronary artery (LADCA), the clip was
removed so that the tension on the ligature was released and reperfusion occurred for 2 h. PBS
(PBS+0.01%DMSO), CR-AnxA12-50 (5μg/mouse) or CR-AnxA12-48 (5μg/mouse) were admin-
istered via i.v. injection and blood was collected 2h post reperfusion. The doses and time inter-
vals were selected based on published findings with CR-AnxA12-50 and related native peptide
[17]. Plasma CCL5 (R&D System, Abingdon, UK) was measured using ELISA and following
manufacturer’s instructions. Two hours later, the LADCA was then re-occluded and mice
injected with Evans blue dye (1ml, 2% wv-1) staining the perfused and viable myocardium,
leaving the occluded and necrotic vascular bed uncolored. The heart was removed the left ven-
tricle (LV) excised and weighed. This was then sectioned and the area at risk (AR) was
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separated from the non-ischaemic myocardium. To distinguish between ischemic and
infarcted tissue, the AR was cut into small pieces and incubated with p-nitro-blue tetrazolium
(NBT, 0.5 mgml-1, 20 min, 37˚C).
Statistics
Results are presented as mean ± SEM. Statistical analysis was performed using the paired,
unpaired Student’s t test, or one-way ANOVA followed by a Dunnett’s post hoc test as appro-
priate. In all instances P<0.05 was considered to be significant.
Results
CR-AnxA12-48 displays elevated resistance to neutrophil mediated
degradation and binds ALX with high affinity
Results from published studies indicated that in addition to Valine25; Alanine49 and Alanine50
were also found to be important recognition sites for neutrophil protease enzymes [17]. There-
fore, we designed a peptide that in addition to having a substitution of Valine25 to Leucine,
which we previously found to confer resistance to proteinease-3 and neutrophil elastae [17],
also lacked Alanines at positions 49 and 50 (Fig 1A). Incubation of this peptide, coined
CR-AnxA12-48, with activated human neutrophils demonstrated that removal of these two
amino acids conferred a significant increase in resistance to neutrophil mediated cleavage
when compared to its parent peptide CR-AnxA12-50 (Fig 1B).
We next tested whether the modifications influenced its affinity to the ALX receptor. For
this purpose we incubated HEK cells overexpressing the human ALX receptor and tested the
ability of CR-AnxA12-48 to competitively displace a radiolabelled tracer [13]. Incubation
CR-AnxA12-48 with I
125 labelled Ac2-26 peptide [22] demonstrated that CR-AnxA12-48 dis-
played a high affinity to the ALX receptor with an IC50 of 20nM (Fig 1C). Of note, incubation
of CR-AnxA12-48 with FPR1-HEK cells did not produce specific competition curves in the
presence of the same tracer (Fig 1D). We next tested whether this peptide also activated the
ALX receptor. For this purpose we utilized the β-Arrestin PathHunter system where ligand
binding leads to a luminescent signal. Incubation of ALX-overexpressing HEK cells with
CR-AnxA12-48 lead to a dose dependent increase in luminescent signal that displayed a
characteristic bell shape does response (Fig 1E). Together these results demonstrate that
CR-AnxA12-48 displays higher resistance to neutrophil degradation, while retaining a high
degree of affinity and specificity to the pro-resolving receptor ALX.
Pro-resolving and anti-inflammatory actions of CR-AnxA12-48 are
mediated by ALX
Having found that CR-AnxA12-48 activated ALX we next tested whether it carried anti-inflam-
matory and pro-resolving actions through this molecular target. We first assessed its ability to
promote efferocytosis of apoptotic neutrophils a key step in the resolution of inflammation
[3]. Incubation of murine macrophages with CR-AnxA12-48 led to a dose dependent increase
in macrophage efferocytosis (40–80%; Fig 2A). The activity of this peptide at promoting effero-
cytosis was also found to be comparable to that displayed by its parent peptide CR-AnxA12-50
(Fig 2A). We next tested whether the murine orthologue of the ALX receptor was responsible
for mediating this pro-resolving action of CR-AnxA12-48. Incubation of cells lacking the ALX
receptor with CR-AnxA12-48 did not lead to a significant increase in macrophage efferocytosis
when compared with cells incubated with PBS alone (Fig 2B).
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Having assessed the ability of the new AnxA1-derived peptide in regulating macrophage
response, we next investigated whether the actions of CR-AnxA12-50 on neutrophil reactivity
[17] were retained with CR-AnxA12-48. Incubation of this peptide with isolated human neutro-
phils gave concentration-dependent decreases in neutrophil interactions to activated primary
endothelial cells. This was reflected in significant decreases in both the numbers of adherent as
well as rolling cells on the endothelial monolayer (Fig 2C). Incubation of human neutrophils
with a neutralizing antibody to the ALX receptor reversed this biological action, reverting the
Fig 1. CR-AnxA12-48 is resistant to neutrophil mediated cleavage and selectively binds the ALX receptor. (A) Aminoacid sequences
for CR-AnxA12–50 and CR-AnxA12–48 (B) Plots depicting the amount of peptide remaining at the indicated intervals in incubations of human
neutrophil with CR-AnxA12–50 or CR-AnxA12–48. Results are mean ± SEM of n = 4 distinct incubations with different neutrophil preparations.
*p < 0.05 versus AnxA12–48 incubations. (C,D) Binding affinity of CR-AnxA12–48 to (C) human ALX-overexpressing and (D) FPR1-
overexpressing HEK cells was assessed in a competitive binding assay using [125I]–Ac2-26. (E) Agonist activity of CR-AnxA12–48 was
investigated using β-arrestin stably expressing FPR2/ALX. Results for C-E are mean ± SEM of 3–4 independent experiments.
https://doi.org/10.1371/journal.pone.0175786.g001
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Fig 2. Anti-inflammatory and pro-resolving actions of CR-AnxA12-48 with mouse and human
leukocytes. (A) Plots depicting phagocytosis of apoptotic human neutrophils (efferocytosis) by macrophages
incubated with or without the indicated concentrations of CR-AnxA12–50 and CR-AnxA12–48. (B) Bar graphs
depicting phagocytosis of apoptotic human neutrophils (efferocytosis) by bone marrow derived macrophages
from Alx/Fp2/3-/- mice incubated with or without the indicated concentrations of CR-AnxA12–48. Results are
mean ± SEM. n = 4 mice per group per time point; *p < 0.05, **p < 0.01, versus vehicle group. (C) Plots
depicting the number of human neutrophils interacting with activated human endothelial cells incubated with
or without the indicated concentrations of CR-AnxA12–48.. (D) Bar graphs illustrating the number of
neutrophils interacting with activated endothelial cells. Results for C,D are mean ± SEM of n = 4 independent
cellular preparations *p < 0.05 versus PBS, **p < 0.01 versus vehicle control.
https://doi.org/10.1371/journal.pone.0175786.g002
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number of cells interacting with the activated vascular endothelial cells back to levels observed
in vehicle control cells (Fig 2D). These actions were also specific to the ALX receptor since
incubation of neutrophils with an isotype control antibody did not reverse the biological
actions of CR-AnxA12-48 (Fig 2D). Together these findings demonstrate that CR-AnxA12-48
displays potent leukocyte directed anti-inflammatory and pro-resolving actions that are medi-
ated by the receptor ALX.
CR-AnxA12-48 potently regulates neutrophil recruitment in vivo
Since CR-AnxA12-48 displayed potent biological actions with isolated leukocytes we next tested
its ability to regulate leukocyte responses in vivo. For this purpose we used the IL-1β initiated
air-pouch model of dermal inflammation. Administration of IL-1β to mice gave a robust leuko-
cyte influx, with neutrophils being the predominant cell type. Administration of CR-AnxA12-48
immediately prior to the onset of inflammation gave dose-dependent decreases in both the
total number of leukocytes and the number of neutrophils, identified as Ly6G+ cells, recruited
into the pouches (Fig 3). This reduction in neutrophil recruitment was displayed with doses as
low as 5ng/mouse where we found> 60% decrease in the number of neutrophils recruited to
the site of inflammation. In these experimental settings, CR-AnxA12-48 was more potent then
the parent peptide CR-AnxA12-50. Thus, these results demonstrate that CR-AnxA12-48 carries
leukocyte directed actions in vivo, with higher potency than CR-AnxA12-50.
CR-AnxA12-48 is cardioprotective during ischemia-reperfusion mediated
tissue injury
Next we tested whether CR-AnxA12-48 also displayed tissue protective actions during car-
diac-ischemia reperfusion where leukocyte migration and activation leads to tissue damage
Fig 3. CR-AnxA12–48 regulated neutrophil recruitment in vivo. Graphs illustrate (A) total leukocyte numbers and (B) the
number of Ly6G+ cells quantified using light microscopy and flow cytometry (see Materials and Methods for details). Results
are mean ± SEM of n = 4 mice per group; *p < 0.05, **p < 0.01, versus vehicle group.
https://doi.org/10.1371/journal.pone.0175786.g003
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[23]. Ligation of the left descending coronary artery for 25 min and reperfusion for 120 min
led to marked damage within the left ventricle where ~50% of the area at risk was compro-
mised, corresponding to ~20% of the left ventricle (Fig 4A–4C). Administration of CR-
AnxA12-48 immediately prior to reperfusion gave significant protection, reducing the amount
of damaged tissue by >50% when compared to vehicle control (Fig 4B and 4C). In addition,
CR-AnxA12-48 also reduced plasma levels of the pro-inflammatory cytokine chemokine (C-C
motif) ligand 5 or CCL5 (Fig 4D).
Discussion
In the present study we characterized the biological actions of a novel AnxA1-derived peptide.
Results from these experiments demonstrate that CR-AnxA12–48 displays increased stability to
neutrophil mediated degradation when compared to its parent peptide (Fig 1). This peptide
also displayed a high affinity to the pro-resolving receptor ALX via which it exerted its potent
anti-inflammatory and pro-resolving actions on phagocytes (Figs 1 and 2). Administration of
CR-AnxA12–48 to experimental animals, demonstrated that the biological actions identified in
vitro were retained in vivo, where this peptide regulated neutrophil trafficking and displayed
tissue-protective properties during leukocyte mediated tissue damage (Figs 3 and 4).
Fig 4. CR-AnxA12–48 displays cardioprotective actions in murine ischemia reperfusion mediated
injury. Graphs depict (A) Relative area at risk to total ventricle size in each group (B-C) Quantitative analyses
for tissue damage expressed as (B) infarct size/area at risk and (C) infarct size/left ventricle. (D) Plasma
CCL5 concentrations. Results are mean ± SEM of n = 6 mice per group. **p < 0.01 versus Vehicle group.
https://doi.org/10.1371/journal.pone.0175786.g004
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Recent studies suggest that utilizing therapeutics which harness processes within the reso-
lution of acute inflammation rather then inhibiting inflammation altogether may yield ther-
apeutics that are devoid of the unwanted side effects associated with current medicines [4, 5,
24]. AnxA1 is a pro-resolving protein that regulates immune response to promote the termi-
nation of both acute and chronic inflammation [25]. Studies assessing the activity of this
protein indicate that AnxA1 loses its protective actions during ongoing inflammation [17,
19, 26]. In this aspect several mechanisms are now appreciated to lead to this reduced activ-
ity, these include the down regulation of its cognate receptor ALX, the decrease in expres-
sion of the protein and increased cleavage of the n-terminal portion, the pharmacophore of
the protein [12, 27]. Given that AnxA1 reprograms the host immune response to terminate
inflammation and in doing so does not interfere with the host’s ability to combat infections
[28] recent studies have investigated the actions of peptides derived from the N-terminal
portion of this protein as potential therapeutic leads [17, 29–31]. In this context, peptides
spanning the first 50 amino acids of the AnxA1 N-terminal regulate both murine and
human leukocyte responses activating resolution programs [17]. Assessment of the cleavage
patterns by neutrophil proteinase enzymes identified several recognition sites for protein-
ase-mediated degradation of these peptides [17]. Thus, in the present study we designed a
new peptide that displayed enhanced resistance to neutrophil-mediated degradation by
modifying two of the recognition sites. The first was the substitution Valine25 to Leucine
that we previously found to increase stability while not altering function of the peptide and
the second was to remove Alanine49 and Alanine50 (Fig 1) and [17]. These modifications
yielded a peptide that retained the leukocyte directed actions of the natural sequence (Figs
2,3 and 4 and [17]) with enhanced stability towards neutrophil mediated degradation when
compared to both the natural sequence [17] and the cleavage resistant peptide we previously
designed (Fig 1).
The ALX receptor is a G-protein coupled receptor that mediates the biological actions of a
number of pro-resolving molecules including the essential fatty acid derived specialized pro-
resolving mediators Resolvin D1, Resolvin D3 and Lipoxin A4 [32]. Of note, this receptor
also mediates some of the biological actions of the acute phase protein Serum Amyloid A and
is suggested to recognize endogenous formlyated peptides, although the binding affinity to
the formylated peptide fMLF to ALX is about a log order lower then that to FPR1 [33]. Recent
studies demonstrate that only pro-resolving molecules, including AnxA1, are able to promote
the homodimerization of the ALX receptor, a process that leads to the activation of a host
protective signalling cascade involving a p38/MAPK-activated protein kinase/heat shock pro-
tein 27 signalling signature [27]. In the present studies we found CR-AnxA12–48 retained a
high affinity to ALX with an IC50 of 20nM and displayed a characteristic bell-shaped dose
response in its ability to activate this receptor (Fig 1). This bell shape response is also reflected
in its ability to regulate neutrophil responses in vitro and in vivo, an action that is in line with
that protective properties of AnxA1 [12] as well as other pro-resolving agonists to this recep-
tor [34].
In summation, results from the present experiments provide evidence for the potent biolog-
ical actions of CR-AnxA12–48, a peptide derived from the pharmacophore of the pro-resolving
and tissue protective protein AnxA1. This peptide in addition to displaying enhanced stability
to human neutrophil-mediated cleavage, also exerts potent (fM) leukocyte directed actions
regulating host responses during acute inflammation and protects the heart from leukocyte
mediated tissue damage. Thus, taken together these findings characterize a novel pro-resolu-
tion agonist to the ALX receptor that may be used to treat ongoing inflammation without
interfering with the host immune response.
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